Pancreatic ductal adenocarcinoma (PDAC) is among the most fatal of malignancies with an extremely poor prognosis. The objectives of this study were to provide a detailed understanding of PDAC pathophysiology in view of the host immune response. We examined the PDAC tissues, sera, and peripheral blood cells of PDAC patients using immunohistochemical staining, the measurement of cytokine ⁄ chemokine concentrations, gene expression analysis, and flow cytometry. The PDAC tissues were infiltrated by macrophages, especially CD33+CD163+ M2 macrophages and CD4+ T cells that concomitantly express programmed cell death-1 (PD-1). Concentrations of interleukin (IL)-6, IL-7, IL-15, monocyte chemotactic protein-1, and interferon-c-inducible protein-1 in the sera of PDAC patients were significantly elevated. The gene expression profile of CD14+ monocytes and CD4+ T cells was discernible between PDAC patients and healthy volunteers, and the differentially expressed genes were related to activated inflammation. Intriguingly, PD-1 was significantly upregulated in the peripheral blood CD4+ T cells of PDAC patients. Correspondingly, the frequency of CD4+PD-1+ T cells was increased in the peripheral blood cells of PDAC patients, and this increase correlated to chemotherapy resistance. In conclusion, inflammatory conditions in both PDAC tissue and peripheral blood cells in PDAC patients were prominent, highlighting monocytes ⁄ macrophages as well as CD4+ T cells with influence of the clinical prognosis.
Pancreatic ductal adenocarcinoma (PDAC) is among the most fatal of malignancies with an extremely poor prognosis. The objectives of this study were to provide a detailed understanding of PDAC pathophysiology in view of the host immune response. We examined the PDAC tissues, sera, and peripheral blood cells of PDAC patients using immunohistochemical staining, the measurement of cytokine ⁄ chemokine concentrations, gene expression analysis, and flow cytometry. The PDAC tissues were infiltrated by macrophages, especially CD33+CD163+ M2 macrophages and CD4+ T cells that concomitantly express programmed cell death-1 (PD-1). Concentrations of interleukin (IL)-6, IL-7, IL-15, monocyte chemotactic protein-1, and interferon-c-inducible protein-1 in the sera of PDAC patients were significantly elevated. The gene expression profile of CD14+ monocytes and CD4+ T cells was discernible between PDAC patients and healthy volunteers, and the differentially expressed genes were related to activated inflammation. Intriguingly, PD-1 was significantly upregulated in the peripheral blood CD4+ T cells of PDAC patients. Correspondingly, the frequency of CD4+PD-1+ T cells was increased in the peripheral blood cells of PDAC patients, and this increase correlated to chemotherapy resistance. In conclusion, inflammatory conditions in both PDAC tissue and peripheral blood cells in PDAC patients were prominent, highlighting monocytes ⁄ macrophages as well as CD4+ T cells with influence of the clinical prognosis. P ancreatic ductal adenocarcinoma (PDAC) is one of the most fatal solid malignancies with a 5-year survival rate of <5% and a median survival of 4-6 months in Japan as well as in other countries. (1, 2) Surgical resection is the only method for achieving radical treatment; however, only 15-20% of patients are diagnosed in the operable early stage. (3) For unresectable PDAC, gemcitabine-based chemotherapeutic regimens are efficacious; however, improvements in survival are limited to only several months, and no complete remission is fundamentally expected. (4) Therefore, it is extremely important to understand the pathophysiology of PDAC in order to establish novel diagnostic methods for early detection as well as to develop novel effective therapies.
Cancer is frequently associated with inflammation induced by the host immune system, (5) involving a variety of immune-mediating cells, including the Th1 helper T cells and cytotoxic T lymphocytes, (6) which inhibit cancer progression, and the myeloid-derived suppressor cells (7) and regulatory T cells, (8) which are cancer-promoting inflammatory cells. These anticancer and cancer-promoting immune-mediating cells have a complex involvement in the persistent inflammation associated with cancer that influences the patient's prognosis. Some inflammatory cells such as regulatory T cells, myeloid-derived suppressor cells, as well as humoral mediator interleukin (IL)-6, are reported to be involved in PDAC; (9) however, details of the systemic inflammatory condition of PDAC has not been sufficiently studied. Accordingly, the purpose of this study was to elucidate the systemic inflammatory state of PDAC by investigating the inflammatory markers in the local cancer tissue, serum, and peripheral blood.
Materials and Methods
Patients and pancreatic ductal adenocarcinoma tissues. Twenty specimens that were surgically removed from PDAC patients (Table 1) were used for pathological analysis. Both PDAC patients and healthy volunteers were enrolled after providing informed consent prior to the serum concentration analysis of cytokines and chemokines, gene expression analysis of peripheral blood cells, and flow cytometry analysis. The clinical characteristics of the study participants are provided in Tables  S1-S3 . The clinical stages were evaluated in accordance with the TNM staging system for pancreatic carcinoma issued by the Union of International Cancer Control (7th edition). The therapeutic effect of chemotherapy was assessed in terms of partial responsiveness, stable disease, and progressive disease in accordance with the Response Evaluation Criteria in Solid Tumors. The study was approved by the institutional review board and was carried out in accordance with the Declaration of Helsinki.
Isolation of peripheral blood mononuclear cells. Peripheral blood was obtained prior to any treatments for PDAC. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous blood using Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich, St. Louis, MO, USA), as previously described. (10) The obtained fraction of PBMCs was incubated with bead-labeled anti-CD4, anti-CD8, anti-CD14, or anti-CD15 antibodies (Miltenyi, Cologne, Germany), followed by isolation using a magnet.
Additional procedures. Additional materials and methods are presented in Data S1.
Results
Features of local immune-mediating cells in PDAC tissues. To elucidate local inflammatory conditions of PDAC, we immunohistochemically analyzed the surgically resected PDAC tissues. We found that CD33+ myeloid cells markedly infiltrated PDAC tissues (Fig. 1a,b , Table 1 ). Neutrophil elastase-positive cells were rarely observed among CD33+ cells (Fig. 1c) , suggesting that CD33+ myeloid-lineage cells were likely monocytes ⁄ macrophages. There was a fraction of CD14+ cells (Fig. 1d ,e, Table 1 ) and a more prominent fraction of CD163+ monocytes ⁄ macrophages among CD33+ cells (Fig. 1f,g , Table 1 ), indicating infiltration of M2 suppressive macrophages. Lymphoid follicles were observed adjacent to PDAC tissues, where most of the infiltrating lymphocytes were CD3+ T cells (Fig. 1h) . Among infiltrating CD3+ T cells, CD4+ T cells were predominant compared to the CD8+ T cells (Fig. 1i,j) . T-bet+ cells were not frequently observed (Fig. 1k) , whereas FoxP3+ cells as well as programmed cell death-1 (PD-1)+ cells were more frequently observed (Fig. 1l,m , Table 1 ), suggesting that regulatory or activated CD4+ T cells had infiltrated the PDAC tissues.
Serum cytokine and chemokine concentration in PDAC patients.
We next assessed concentration level of panels of cytokines and chemokines in sera of PDAC patients (Table S1 ). Serum concentrations of the cytokines IL-6, IL-7, and IL-15 were significantly elevated in PDAC patients compared to healthy volunteers (Fig. 2) . Among chemokines, monocyte chemotactic protein-1 (MCP-1) and interferon-c-inducible protein-10 (IP-10) were significantly elevated, and IL-8 was relatively high in PDAC patients, although this was not statistically significant (P = 0.06; Fig. 2 ). We used real time detection-PCR (RTD-PCR) to measure the expression levels of mRNAs encoding these cytokines and chemokines in CD14+ monocytes ⁄ macrophages and CD4+ T cells of PDAC patients. We found that IL-15 expression by CD14+ monocytes ⁄ macrophages and IL-6 and IL-7 expression by CD4+ T cells of PDAC patients were significantly upregulated compared to those of healthy volunteers (Fig. S1 ), suggesting that peripheral CD14+ monocytes ⁄ macrophages and CD4+ T cells contribute to the elevations in cytokine levels evident in the sera of PDAC patients. Such cells are the local macrophages and CD4+ T cells associated with inflammation of PDAC tissues.
Distinct gene expression profile of CD14+ monocytes and CD4+ T cells in PBMCs of patients with PDAC. Local infiltrating inflammatory cells and serum cytokine ⁄ chemokine elevation highlighted macrophages and CD4+ T cells in the context of PDAC inflammation. We further examined whether peripheral blood cells were affected using gene expression analysis with DNA microarray. Unsupervised clustering analysis of gene expression showed a clear gene expression pattern for all blood cells (Fig. 3a) , which was consistent with our previous report. (11) The analysis of peripheral blood cell subfractions in PDAC patients showed a discernible gene expression profile of the CD14+ monocyte and CD4+T cell fractions (Fig. 3b,c) , whereas CD8+ and CD15+ cell fractions did not (Fig. 3d,e) . Unsupervised analysis of the gene expression profile in isolated CD14+ monocytes and CD4+ T cells in a larger cohort (Table S3 ) also showed relatively discernible clusters for PDAC patients and healthy volunteers (Fig. 4a,c) . Significantly altered gene expression by ≥1.5-fold in peripheral CD14+ monocytes of PDAC patients compared to healthy volunteers was observed in 261, 126, and 85 genes at P-values of <0.05, <0.01, and <0.005, respectively. Most of these genes were upregulated (177 ⁄ 261, 87 ⁄ 126, and 61 ⁄ 85, respectively). The numbers of significantly altered genes by ≥1.5-fold in CD4+ cells were 690, 496, and 419 with P-values of <0.05, <0.01, and <0.005, respectively. Most of these were also upregulated (459 ⁄ 690, 349 ⁄ 496, and 298 ⁄ 419, respectively). Unsupervised analysis of the gene expression profile using the 261 significantly altered genes from CD14+ monocytes and 496 genes from CD4+ T cells showed distinct clusters for PDAC patients and healthy volunteers (Fig. 4b,d) .
The biological process networks related to the 261 genes, whose expression was significantly altered ≥1.5-fold in CD14+ monocytes ⁄ macrophages of PDAC patients, included the cell cycle, inflammation, blood coagulation, cell adhesion, and development ( Table 2 ). We randomly selected 17 genes from the list of those 50 most significantly upregulated upon microarray analysis (Table 3) , and measured transcriptional expression levels by RTD-PCR. We found that most of these genes were indeed upregulated, including the adhesion-related gene CD226 and the cell cycle-related gene CDK6 (Table S4) . Biological process networks related to the 496 genes whose expression was significantly altered ≥1.5-fold in CD4+ T cells of PDAC patients mostly included the cell cycle and inflammation as well as DNA damage and apoptosis (Table 4 ). We randomly selected 18 genes from the list of those 50 most significantly upregulated, as revealed by microarray analysis (Table 5) , and measured transcriptional expression levels using RTD-PCR. We found that most of these genes were indeed upregulated, including the cell cycle-associated gene PTTG1 and the apoptosis-related gene BAX (Table S4) . Interestingly, PD-1, which is expressed on the activated T cell to attenuate the T cell receptor signaling pathway, was also included (Table 5) . Thus, CD14+ monocytes and CD4+T cells were the meaningfully affected subpopulations of peripheral blood cells in PDAC patients. low/À population, (12) was greater in the peripheral blood of PDAC patients (Fig. 5c) ; however, FoxP3 gene expression was not significantly elevated in CD4+ T cells of PDAC patients ( T  cells  and  CD4+CD25+CD127 low/À cells were not correlated (Fig. 5d ). Neither the frequency of CD4+PD-1+ T cells nor CD4+CD25+CD127 low/À T cells was associated with cancer progression stages (Fig. 5e,f) . However, patients whose responsiveness to chemotherapy were progressive disease tended to show a relatively high frequency of CD4+PD-1+ cells in the peripheral blood compared to patients with a diagnosed therapeutic effect of stable disease or partial responsiveness with chemotherapy, whereas this was not observed for CD4+CD25+CD127 low/À T cells (Fig. 5g,h ). We PK-S3 PK-S1 PK-S4 PK-S2 PK-S5 Healthy-S7 Healthy-S1 Healthy-S2 Healthy-S3 Healthy-S4 Healthy-S5 Healthy-S6 Fig. 3 . Unsupervised clustering analysis of gene expression profiles of subfractions of peripheral blood cells from patients with pancreatic ductal adenocarcinoma (PK; n = 7) and healthy volunteers (n = 5). RNA was isolated from entire blood cells or each subfraction of peripheral blood cells, followed by gene expression analysis using DNA microarray. Genes that passed the quality check control were used in each clustering analysis. divided PDAC patients into two groups: one with ≥10% CD4+PD-1+ T cells, and the other with <10% of such cells in peripheral blood. The overall survival of the former group was relatively shorter than that of the latter group. However, the P-value (P = 0.111) indicated that statistical significance was not attained. These data suggest that the subpopulation of peripheral CD4+ T cells from PDAC patients contained the important subfraction of activated and exhausted CD4+PD-1+ T cells, which may influence the therapeutic effect of chemotherapy.
Discussion
In the current study, we examined systemic inflammatory conditions of PDAC by analyzing the PDAC tissues, sera, and peripheral blood cells. We observed that the PDAC tissues were remarkably infiltrated by monocytes ⁄ macrophages and CD4+ T cells, especially M2-phenotype macrophages and PD-1+ cells. Serum concentrations of IL-6, IL-7, IL-15, MCP-1, and IP-10 were elevated in PDAC patients, suggesting humoral inflammatory mediators related to the macrophages and CD4+ T cells were present in the blood of PDAC patients. In addition, we observed distinctively different gene expression profiles of CD14+ monocytes and CD4+ T cells among subfractions of peripheral blood cells between PDAC patients and healthy volunteers. Cell cycle processes as well as inflammation-associated biological processes were commonly related to upregulated genes in the CD14+ monocytes and CD4+ T cells of PDAC patients. More intriguingly, PD-1, an important molecule that is upregulated in activated T cells and attenuates T cell receptor signaling, was upregulated in the CD4+ T cells of PDAC patients. The frequency of CD4+PD-1+ T cells was increased and correlated with a resistance to chemotherapy.
Pathologically, PDAC tissues were substantially infiltrated by monocytes ⁄ macrophages and CD4+T cells. Monocytes ⁄ macrophages are generally considered to be involved in nonspecific innate immunity; they digest antigens in the presence of pro-inflammatory cytokines. (13) In the context of cancer immunity, two important subsets of monocytes ⁄ macrophages have been recognized, M1 and M2 macrophages. (14) M1 macrophages play a principal role in anticancer immunity, whereas M2 macrophages sustain or promote cancer growth by inhibiting anticancer immunity. We observed a substantial number of CD163+ cells among CD33+ and neutrophil elastase-negative macrophages, suggesting an M2 macrophage phenotype (15) in PDAC tissues, which presumably contributes to sustained cancer growth.
Among infiltrated CD4+ T cells in PDAC tissues, the expression of FoxP3 and PD-1 was frequently observed. FoxP3 is a transcriptional factor that is suggestive of activated T cells as well as regulatory T cells. (16) PD-1 is a receptor, whose expression is induced in activated T cells, attenuating the signal transduced from a T cell receptor encountered by a cognate antigen. (17) (18) (19) These inflammatory features of PDAC tissues highlight monocytes ⁄ macrophages and CD4+ T cells, especially M2 macrophages and exhausted CD4+PD-1+ T cells, which may contribute to cancer progression.
Previously, we observed that the gene expression profile of total blood cells from patients with digestive cancers was distinct from that of healthy volunteers. (11) This is consistent with the current study, in which the gene expression profile of CD14+ monocytes and CD4+ T cells in PBMCs as well as entire blood populations was distinct between PDAC patients and healthy volunteers. Affected genes, most of which were upregulated, were related to cell cycle and inflammation processes in CD14+ monocytes and CD4+ T cells; this suggests that these inflammatory cells in the peripheral blood were in an activated Original Article www.wileyonlinelibrary.com/journal/cas Komura et al. state. Significantly affected genes in CD14+ monocytes were also related to blood coagulation, cell adhesion, and the developmental regulation of angiogenesis, all of which are important biological processes of activated macrophages. However, it remains to be elucidated whether the immunological consequence of activation of monocytes ⁄ macrophages in peripheral blood cells anti-cancer or cancer promoting effect inhibits or promotes cancer development. Affected genes in CD4+ T cells were also related to DNA damage and apoptosis. CD4+ T cells undergo activationinduced cell death through Fas-mediated signaling, (20) and Fas (CD95) was among the most upregulated genes. Taken together, gene expression analysis disclosed that myeloidlineage CD14+ monocytes ⁄ macrophages and CD4+ T cells are important affected fractions of immune-mediating cells in the peripheral blood cells of PDAC patients, with the implication of a cancer-associated activated inflammatory condition.
Corresponding to the upregulated expression of the PD-1 gene in the peripheral CD4+T cells of PDAC patients, the frequency of CD4+PD-1+ cells in the peripheral blood of PDAC patients was also increased. Intriguingly, the relatively poor success of chemotherapy correlated with an increased level of CD4+PD-1+ T cells. The overall survival of PDAC patients with ≥10% CD4+PD-1+ T cells was somewhat shorter than that of those with <10% such cells, although statistical significance was not attained. Any underlying role for CD4+PD-1+ T cells in terms of responsiveness to chemotherapy remains to be explored; we observed neither a supporting effect on cancer cell proliferation nor a suppressive effect on IFN-c-secreting activated cytotoxic T cells in vitro (data not shown). PD-1 attenuates T cell receptor signaling, therefore, CD4+ T cells expressing PD-1 are considered to be exhausted if anticancer inflammation is not induced. An increased level of CD4+PD-1+T cells may reflect the fact that the anticancer inflammation induced during chemotherapy is inadequate. Clinical trials featuring blocking of PD-1-expressing cells (using an anti-PD-1 antibody) to enhance anticancer immune reactions are currently underway; this may be a valuable therapy for lung cancer and melanoma, overcoming immune resistance. (21) Although further clinical studies are needed to explore the role played by CD4+PD-1+ T cells in chemotherapy and overall survival, our current finding that CD4+ PD-1+ T cells infiltrate PDAC tissues and increase in proportion among peripheral blood cells suggests that immunotherapy targeting the exhausted PD-1+ population may be a useful novel immunotherapeutic approach toward PDAC. Concentrations of the macrophage-and T cell-related cytokines and chemokines IL-6, IL-7, IL-15, MCP-1, and IP-10 were significantly elevated in the sera of PDAC patients. Interleukin-15, MCP-1, and IP-10 are produced by monocytes ⁄ macrophages, considerably inducing or activating an innate immune reaction. (22) (23) (24) The biological function of the cytokine IL-7 is maintenance of the na€ ıve T cells as well as T cell proliferation, (25) whereas IL-6 is involved in macrophage polarization and in the initiation and proliferation of PDAC. (9) Although elevation of these cytokines ⁄ chemokines is considered to reflect the inflammatory condition of PDAC, the clinical impact of the elevated serum cytokines and chemokines in PDAC should be further studied in the context of anticancer or cancer-promoting humoral immune reactions.
Although the current study highlighted the importance of focusing on monocytes ⁄ macrophages and CD4+ T cells in local PDAC tissues as well as peripheral blood, these immunemediating populations are heterogeneous and extremely complex. The increased frequency of CD4+PD-1+ T cells, which are presumably an important population affecting host immunity against cancer, suggest that significant subfractions in monocytes ⁄ macrophages and the CD4+ T cell population may exist. Additional detailed studies are needed to identify which subfractions are significantly associated with the clinical prognosis of PDAC patients and to verify the clinical impact of the subfractions in well-designed clinical trials.
In conclusion, the current study showed that PDAC is associated with a systemic inflammatory condition, highlighting the presence of activated monocytes ⁄ macrophages and CD4+ T cells, which are presumed to be exhausted both in local cancer tissues and peripheral blood. Substantial infiltration of cancer-promoting immune cells, including M2 macrophages, in local cancer tissues was concomitant with the increased expression of PD-1 in T cells as well as the increased frequency of CD4+PD-1+ T cells in the peripheral blood of PDAC patients. This may contribute, in part, to persistent chronic inflammation as a consequence of failure to eliminate cancer despite the host immune response. However, the immune system includes both cancer-promoting immune-mediating cells and anticancer inflammatory cells. Further studies focusing on monocyte ⁄ macrophage and CD4+ T cell subfractions in PDAC patients may reveal further details regarding the PDAC immune condition, and such information may be helpful in the development of novel diagnostic markers for detecting PDAC. It may also provide meaningful insights into the development of novel immunological therapeutic approaches for modulating the inflammatory condition in PDAC toward anticancer inflammation. Original Article Inflammatory features of pancreatic cancer www.wileyonlinelibrary.com/journal/cas
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